BCM
LXRX icon

Bayesian Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Bayesian Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-42,000
Closed -$31K – 808
2024
Q4 		$31K Buy
+42,000
New +$50.6K ﹤0.01% 643
2024
Q1 		– Sell
-32,119
Closed -$49.1K – 971
2023
Q4 		$49.1K Buy
+32,119
New +$38.2K 0.01% 678
2021
Q1 		– Sell
-16,300
Closed -$56K – 630
2020
Q4 		$56K Buy
+16,300
New +$31.1K 0.01% 425
2016
Q1 		– Sell
-11,700
Closed -$156K – 400
2015
Q4 		$156K Buy
+11,700
New +$144K 0.22% 196

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $12.3B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return